- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Guggenheim Cuts GRAIL Price Target to $75
Analysts remain bullish on the cancer detection company despite lowered expectations
Mar. 30, 2026 at 3:38pm
Got story updates? Submit your updates here. ›
Guggenheim Securities has reduced its price target for GRAIL (NASDAQ:GRAL) from $130 to $75, though the firm maintains a 'buy' rating on the stock. Several other analysts have also lowered their price targets for the cancer detection company in recent months, citing market conditions and competitive pressures.
Why it matters
GRAIL is a pioneering biotech company working on early cancer detection through advanced blood tests. Its technology has significant potential to transform cancer screening, but the company faces challenges as it works to commercialize its products and fend off competition. Analysts remain broadly optimistic about GRAIL's long-term prospects, though near-term headwinds have prompted some to temper their short-term expectations.
The details
Guggenheim cited a range of factors in its decision to lower GRAIL's price target, including market conditions and the competitive landscape. The firm noted that while it still sees significant upside potential for GRAIL, the company faces near-term pressures that have impacted its valuation. Other analysts have also recently cut their price targets for GRAIL, with Morgan Stanley dropping its target from $110 to $60 and Canaccord Genuity Group lowering its target from $105 to $80.
- GRAIL reported its latest quarterly results on February 19, 2026.
- Guggenheim issued its updated price target and rating on GRAIL on March 30, 2026.
The players
GRAIL
A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test.
Guggenheim
A financial services firm that provides investment banking, asset management, and capital markets services.
Morgan Stanley
A global financial services firm that provides investment banking, securities, wealth management and investment management services.
Canaccord Genuity Group
An independent global capital markets firm that provides investment banking, advisory, equity research, sales and trading services.
What’s next
Investors will be closely watching GRAIL's progress as it works to commercialize its cancer detection technology and fend off competition. The company's next earnings report, expected in late April or early May 2026, will provide an update on its financial performance and business developments.
The takeaway
GRAIL's pioneering work in early cancer detection has attracted significant investor interest, but the company faces near-term headwinds that have prompted analysts to temper their short-term expectations. While the long-term potential remains strong, GRAIL will need to navigate a challenging competitive landscape and market conditions to achieve its ambitious goals.
